The North America Cardiovascular Digital Solutions Market should witness market growth of 3.6% CAGR during the forecast period (2022-2028).
Digital solutionshave become a suitable accompanimentto traditional medicine due to their many advantages. These include simplicity of use, shortened development times, flexible delivery platforms, lower treatment costs, personalized treatment options, and improved medication adherence. The overall market is anticipated to increase consistently over time, given the advantages provided by these solutions and the increased desire for digital andremote solutions globally following the pandemic.
Ischemic heart disease, cardiomyopathies, cerebrovascular disease,arrhythmias, rheumatic heart disease, peripheral vascular disease,congenital heart disease, hypertensive heart disease, and other disorders are included in the broad category of CVD. Although non-modifiable factors (such as genetics, age, and sex) are equally significant, mostCVD is hastened by mainly metabolic risk factors and modifiable behavioral. The majority of available scientific data currently favors the application of digital technologies in the treatment and management of CVD.
A significant shift has taken place in the US in Cardiovascular care from volume-based, fee-for-service (FFS) payment models tothose centered on quality as well as patient outcomes. As a result, value-based care (VBC) payment schemes are available in a spectrum of risk and competency requirements. The transition to VBC payment structures is altering the economics of cardiology providers and putting MedTech manufacturers at risk of commercialization unless they produce unique, significant solutions. In order to encourage new financial structures and provider incentives, MedTech companies are now developingcardiovascular solutions thathave clinical and financial value in addition to product performance. Therefore, in the coming years, the expedited incorporation of digital solutions presents robust growth opportunities for the regional market's growth.
The US market dominated the North America Cardiovascular Digital Solutions Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $34,667.6 Million by 2028. The Canada market is poised to grow at a CAGR of 6% during (2022-2028). Additionally, The Mexico market should witness a CAGR of 5.1% during (2022-2028).
Based on Service Type, the market is segmented into Unobtrusive Testing, CVD Health Informatics, Cardiac Rehab Programs and Others. Based on End-use, the market is segmented into Hospitals & Clinics, Ambulatory Care Centers and Others. Based on Deployment, the market is segmented into Cloud-Based and On-premise. Based on Components, the market is segmented into Devices and Software. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Apple, Inc., General Electric Company, Koninklijke Philips N.V., Verily Life Sciences LLC (Alphabet, Inc.), iRhythm Technologies, Inc., Bardy Diagnostics, Inc. (Hill-Rom Holdings Inc) (Baxter International Inc.), eviCore Healthcare (Express Scripts Holding Company) (Cigna Corporation), AliveCor, Inc., Cardiotrack, and HeartFlow, Inc.
Digital solutionshave become a suitable accompanimentto traditional medicine due to their many advantages. These include simplicity of use, shortened development times, flexible delivery platforms, lower treatment costs, personalized treatment options, and improved medication adherence. The overall market is anticipated to increase consistently over time, given the advantages provided by these solutions and the increased desire for digital andremote solutions globally following the pandemic.
Ischemic heart disease, cardiomyopathies, cerebrovascular disease,arrhythmias, rheumatic heart disease, peripheral vascular disease,congenital heart disease, hypertensive heart disease, and other disorders are included in the broad category of CVD. Although non-modifiable factors (such as genetics, age, and sex) are equally significant, mostCVD is hastened by mainly metabolic risk factors and modifiable behavioral. The majority of available scientific data currently favors the application of digital technologies in the treatment and management of CVD.
A significant shift has taken place in the US in Cardiovascular care from volume-based, fee-for-service (FFS) payment models tothose centered on quality as well as patient outcomes. As a result, value-based care (VBC) payment schemes are available in a spectrum of risk and competency requirements. The transition to VBC payment structures is altering the economics of cardiology providers and putting MedTech manufacturers at risk of commercialization unless they produce unique, significant solutions. In order to encourage new financial structures and provider incentives, MedTech companies are now developingcardiovascular solutions thathave clinical and financial value in addition to product performance. Therefore, in the coming years, the expedited incorporation of digital solutions presents robust growth opportunities for the regional market's growth.
The US market dominated the North America Cardiovascular Digital Solutions Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $34,667.6 Million by 2028. The Canada market is poised to grow at a CAGR of 6% during (2022-2028). Additionally, The Mexico market should witness a CAGR of 5.1% during (2022-2028).
Based on Service Type, the market is segmented into Unobtrusive Testing, CVD Health Informatics, Cardiac Rehab Programs and Others. Based on End-use, the market is segmented into Hospitals & Clinics, Ambulatory Care Centers and Others. Based on Deployment, the market is segmented into Cloud-Based and On-premise. Based on Components, the market is segmented into Devices and Software. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Apple, Inc., General Electric Company, Koninklijke Philips N.V., Verily Life Sciences LLC (Alphabet, Inc.), iRhythm Technologies, Inc., Bardy Diagnostics, Inc. (Hill-Rom Holdings Inc) (Baxter International Inc.), eviCore Healthcare (Express Scripts Holding Company) (Cigna Corporation), AliveCor, Inc., Cardiotrack, and HeartFlow, Inc.
Scope of the Study
By Service Type
- Unobtrusive Testing
- CVD Health Informatics
- Cardiac Rehab Programs
- Others
By End-use
- Hospitals & Clinics
- Ambulatory Care Centers
- Others
By Deployment
- Cloud-Based
- On-premise
By Components
- Devices
- Software
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Apple, Inc.
- General Electric Company
- Koninklijke Philips N.V.
- Verily Life Sciences LLC (Alphabet, Inc.)
- iRhythm Technologies, Inc.
- Bardy Diagnostics, Inc. (Hill-Rom Holdings Inc) (Baxter International Inc.)
- eviCore Healthcare (Express Scripts Holding Company) (Cigna Corporation)
- AliveCor, Inc.
- Cardiotrack
- HeartFlow, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Cardiovascular Digital Solutions Market, by Service Type
1.4.2 North America Cardiovascular Digital Solutions Market, by End-use
1.4.3 North America Cardiovascular Digital Solutions Market, by Deployment
1.4.4 North America Cardiovascular Digital Solutions Market, by Components
1.4.5 North America Cardiovascular Digital Solutions Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 Analyst's Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
3.3.2 Key Strategic Move: (Product Launches and Product Expansions : 2018, Aug - 2022, Nov) Leading Players
Chapter 4. North America Cardiovascular Digital Solutions Market by Service Type
4.1 North America Unobtrusive Testing Market by Country
4.2 North America CVD Health Informatics Market by Country
4.3 North America Cardiac Rehab Programs Market by Country
4.4 North America Others Market by Country
Chapter 5. North America Cardiovascular Digital Solutions Market by End-use
5.1 North America Hospitals & Clinics Market by Country
5.2 North America Ambulatory Care Centers Market by Country
5.3 North America Others Market by Country
Chapter 6. North America Cardiovascular Digital Solutions Market by Deployment
6.1 North America Cloud-Based Market by Country
6.2 North America On-premise Market by Country
Chapter 7. North America Cardiovascular Digital Solutions Market by Components
7.1 North America Devices Market by Country
7.2 North America Software Market by Country
Chapter 8. North America Cardiovascular Digital Solutions Market by Country
8.1 US Cardiovascular Digital Solutions Market
8.1.1 US Cardiovascular Digital Solutions Market by Service Type
8.1.2 US Cardiovascular Digital Solutions Market by End-use
8.1.3 US Cardiovascular Digital Solutions Market by Deployment
8.1.4 US Cardiovascular Digital Solutions Market by Components
8.2 Canada Cardiovascular Digital Solutions Market
8.2.1 Canada Cardiovascular Digital Solutions Market by Service Type
8.2.2 Canada Cardiovascular Digital Solutions Market by End-use
8.2.3 Canada Cardiovascular Digital Solutions Market by Deployment
8.2.4 Canada Cardiovascular Digital Solutions Market by Components
8.3 Mexico Cardiovascular Digital Solutions Market
8.3.1 Mexico Cardiovascular Digital Solutions Market by Service Type
8.3.2 Mexico Cardiovascular Digital Solutions Market by End-use
8.3.3 Mexico Cardiovascular Digital Solutions Market by Deployment
8.3.4 Mexico Cardiovascular Digital Solutions Market by Components
8.4 Rest of North America Cardiovascular Digital Solutions Market
8.4.1 Rest of North America Cardiovascular Digital Solutions Market by Service Type
8.4.2 Rest of North America Cardiovascular Digital Solutions Market by End-use
8.4.3 Rest of North America Cardiovascular Digital Solutions Market by Deployment
8.4.4 Rest of North America Cardiovascular Digital Solutions Market by Components
Chapter 9. Company Profiles
9.1 Apple, Inc.
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Regional Analysis
9.1.4 Research & Development Expense
9.1.5 SWOT Analysis
9.2 General Electric Company
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Segmental and Regional Analysis
9.2.4 Research & Development Expense
9.2.5 Recent strategies and developments:
9.2.5.1 Partnerships, Collaborations, and Agreements:
9.2.5.2 Product Launches and Product Expansions:
9.2.5.3 Acquisition and Mergers:
9.3 Koninklijke Philips N.V.
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Segmental and Regional Analysis
9.3.4 Research & Development Expense
9.3.5 Recent strategies and developments:
9.3.5.1 Partnerships, Collaborations, and Agreements:
9.3.5.2 Product Launches and Product Expansions:
9.3.5.3 Acquisition and Mergers:
9.4 Verily Life Sciences LLC (Alphabet, Inc.)
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Segmental and Regional Analysis
9.4.4 Research & Development Expense
9.4.5 Recent strategies and developments:
9.4.5.1 Product Launches and Product Expansions:
9.5 iRhythm Technologies, Inc.
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Research & Development Expense
9.6 Bardy Diagnostics, Inc.(Hill-Rom Holdings Inc)(Baxter International Inc.)
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Segmental Analysis
9.6.4 Research & Development Expense
9.6.5 Recent strategies and developments:
9.6.5.1 Product Launches and Product Expansions:
9.7 eviCore Healthcare (Express Scripts Holding Company) (Cigna Corporation)
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Segmental Analysis
9.8 AliveCor, Inc.
9.8.1 Company Overview
9.8.2 Recent strategies and developments:
9.8.2.1 Partnerships, Collaborations, and Agreements:
9.8.2.2 Product Launches and Product Expansions:
9.9 Cardiotrack
9.9.1 Company Overview
9.10. HeartFlow, Inc.
9.10.1 Company Overview
Companies Mentioned
- Apple, Inc.
- General Electric Company
- Koninklijke Philips N.V.
- Verily Life Sciences LLC (Alphabet, Inc.)
- iRhythm Technologies, Inc.
- Bardy Diagnostics, Inc.(Hill-Rom Holdings Inc)(Baxter International Inc.)
- eviCore Healthcare (Express Scripts Holding Company) (Cigna Corporation)
- AliveCor, Inc.
- Cardiotrack
- HeartFlow, Inc.
Methodology
LOADING...
